ICH M4Q(R2): What the New CTD Quality Framework Means for CMC

For more than two decades, the Common Technical Document (CTD) has dictated how pharmaceutical and biotech companies organize and present quality information to global regulators. However, the environment generating that data has fundamentally changed.

Programs move faster, therapy modalities are increasingly complex, manufacturing technologies generate vast data volumes, and digital tools are transforming how technical knowledge is exchanged.

The draft ICH M4Q(R2) guideline modernizes the quality portion of the CTD to reflect this digital, lifecycle-oriented reality. While Step 4 adoption and regional implementation are anticipated over the coming years, the implications extend far beyond Regulatory Affairs publishing teams.

Because submission data originates across pharmaceutical development, CMC, analytical testing, manufacturing, quality assurance, engineering, and contract partners, M4Q(R2) raises a broader executive question: How must product, process, and manufacturing knowledge be organized and governed to sustain commercial flexibility throughout the product lifecycle?

The original ICH M4Q framework established standardized locations for quality information within Module 2.3 (Quality Overall Summary) and Module 3 (Quality). M4Q(R2) restructures this relationship entirely.

Rather than functioning as a passive summary of Module 3 reports, Module 2.3 becomes a primary regulatory narrative, communicating the scientific rationale, development logic, and control strategy behind the product. Module 3 provides the granular supporting evidence.

M4Q(R2) introduces and strengthens key concepts across the quality ecosystem:

Under M4Q(R2), Module 2.3 communicates product and manufacturing understanding, development rationale, and control strategy. Condensing technical reports into a high-level overview is no longer sufficient; organizations must explain why their manufacturing and control approaches are scientifically sound.

Because this knowledge originates across Development, Analytical, Manufacturing, CQV, and Quality teams, the strength of the regulatory narrative depends on the continuity of the data behind it. When product knowledge remains trapped in departmental silos or disconnected CDMO reports, establishing a coherent commercial narrative becomes a significant hurdle.

M4Q(R2) introduces Core Quality Information (CQI) to capture the critical quality data that drives risk-based regulatory assessment. Crucially, CQI is not a static record; it remains dynamic throughout the product lifecycle.

As commercial operations evolve — adding new equipment, optimizing yield, updating analytical methods, or onboarding new CDMO sites — organizations must immediately understand which regulatory commitments are impacted. Treating CQI as an active lifecycle asset elevates the strategic necessity of clear data ownership, source-of-truth governance, and end-to-end traceability.

M4Q(R2) places heavy emphasis on the Overall Control Strategy, requiring organizations to prove how individual controls work as an interconnected system:

While the individual technical elements usually exist within an organization, demonstrating their interdependencies across technology transfer and routine manufacturing often reveals significant gaps in enterprise data governance.

M4Q(R2) establishes a far more granular layout for quality data. While separate from ICH M16 (Structured Product Quality Submissions), M4Q(R2) directly supports the industry transition toward structured, reusable data.

Many organizations still manage CMC knowledge in document-centric formats — copying, re-entering, and manually reconciling specifications, process limits, and validation parameters across multiple repositories. As regulatory frameworks become more structured, these data disconnects become active compliance risks, underscoring the need for standardized master data and clear data lineage.

Commercial therapy is rarely static. M4Q(R2) reflects this by embedding Product Lifecycle Management (PLM) directly into the CTD structure, incorporating change summaries and Post-Approval Change Management Protocols (PACMPs).

This establishes a direct operational linkage: manufacturing change control and regulatory lifecycle management must execute in lockstep. A technically sound modification to equipment, raw materials, or facility automation can stall commercial delivery if regulatory impacts, market-specific commitments, or comparability requirements are recognized too late.

Although M4Q(R2) is a regulatory guideline, the data it organizes belongs to the broader enterprise. Treating M4Q(R2) purely as a Regulatory Affairs publishing project creates a dangerous blind spot. While Regulatory Affairs leads the submission strategy, the underlying evidence is owned by Development, Manufacturing, Quality, Validation, IT, and external CDMO networks.

While M4Q(R2) does not impose new standalone requirements for CQV, technology transfer, or computer system assurance, it provides a clear reason to audit how effectively current operating models generate, govern, and maintain critical quality knowledge.

As M4Q(R2) moves toward global harmonization, CMC, Quality, and Operations leaders should evaluate their current information ecosystem:

ICH M4Q(R2) signals a permanent shift in how biopharma quality information is managed. Module 2.3 is becoming an active scientific narrative, Core Quality Information is moving to a lifecycle-managed model, and control strategies are under higher regulatory scrutiny.

The organizations that thrive under this modernized framework will not be those that simply update their publishing software. Success belongs to companies that connect their operational workflows — bridging Development, Manufacturing, Quality, CQV, and IT to ensure product and process knowledge remains connected, traceable, and ready for commercial scale.

AVS Life Sciences helps pharmaceutical and biotechnology organizations build compliant, scalable, and fully integrated operational foundations. We work across functional boundaries to align your manufacturing reality with your regulatory strategy.